News & Events
TraPCAf's Tash Fothergill-Misbah discusses the need for global access to PD Meds
Access to Parkinson’s disease medicines is a global health issue that requires urgent attention. In a recent blog for PLOS, TraPCAf’s Natasha Fothergill-Misbah highlighted the stark reality faced by millions in low- and middle-income countries (LMICs) who cannot access essential treatments.
With over 10 million people living with Parkinson’s worldwide and the global population ageing rapidly, the prevalence of neurological disorders is increasing. By 2050, 80% of the world’s older population will live in LMICs, yet healthcare systems remain largely unprepared. The treatment gap for neurological disorders exceeds 75% in low-income countries, and when medicines are available, costs are often prohibitive—up to $82 per month in Kenya, for example.
The consequences are devastating: worsening symptoms, financial hardship, and social stigma. Some families sell land and livestock just to afford medication, while others go without, suffering needlessly. Yet, change is possible. The WHO’s Intersectoral Global Action Plan (IGAP) aims to improve access to treatment, but more action is needed. Governments, policymakers, and pharmaceutical companies must prioritise making medicines available and affordable.
Beyond research and policy, advocacy through documentary film is shining a light on these challenges. Award-winning films like Shaking Hands With The Devil and UHURU share powerful personal stories, raising awareness and driving action.
You can read the blog post by clicking this link: https://speakingofmedicine.plos.org/2025/03/11/the-need-for-global-access-to-medicines-for-parkinsons-disease/
Make sure to follow our socials!
LinkedIn- www.linkedin.com/in/trapcaf-project
Instagram - www.instagram.com/trapcaf
Last modified: Sat, 15 Mar 2025 21:08:02 GMT